The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication ...

AbbVie (ABBV) on Monday said that the U.S. Food and Drug Administration has approved an update to the indication statement for its drug Rinvoq for the treatment of adults with moderately to severely ...

I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.

The updated indication for the JAK inhibitor allows use in patients with moderately to severely active ulcerative colitis and ...

The Food and Drug Administration (FDA) has approved updated indications for Rinvoq® (upadacitinib) in the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn ...

The Food & Drug Administration granted AbbVie expanded approval for its Rinvoq drug intended to treat moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease ...

AbbVie ABBV remains a dominant force in the immunology space, powered by the continued uptake of its two blockbuster ...

AbbVie has struck deals with Rinvoq generic hopefuls as it extends protection for one of its prized assets until 2037.

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ® (upadacitinib) ...

As in any month, September was eventful for AbbVie. In addition to news about its usual activities, it also scored big with ...

Erica Andersen and Christopher Sipes, co-chairs of Covington’s patent litigation group, and co-counsel David Frazier, the global vice chair of Latham’s intellectual property litigation practice, ...

Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these ...